Cell therapies are among the most promising, yet complex medicines being developed today. Multiply Labs' mission is to make these therapies more widely available by increasing manufacturing efficiency ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced performance results for ...

Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of-concept ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...

By utilizing Multiply Labs' cell therapy robotic cluster and GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour, this ...

Robotic biomanufacturing company Multiply Labs said it has made a significant advance toward its goal of scaling production of cell and gene therapies by using Nvidia’s open Isaac and GR00T robotics ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA’s open ...